Equities

TrivarX Ltd

TrivarX Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (AUD)0.021
  • Today's Change0.00 / 0.00%
  • Shares traded70.02k
  • 1 Year change+5.00%
  • Beta0.8826
Data delayed at least 20 minutes, as of Sep 20 2024 03:06 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Financials data is unavailable for this security.

Inc stmt in AUDIncome statement in AUDView more

Year on year TrivarX Ltd had revenues fall -6.99% from 960.45k to 893.31k, though the company grew net income from a loss of 3.07m to a smaller loss of 1.24m.
Gross margin100.00%
Net profit margin-138.48%
Operating margin-136.98%
Return on assets-12.95%
Return on equity-15.25%
Return on investment-15.25%
More ▼

Cash flow in AUDView more

In 2024, TrivarX Ltd increased its cash reserves by 296.10%, or 633.99k. Cash Flow from Financing totalled 4.32m or 483.79% of revenues. In addition the company used 848.31k for operations while cash used for investing totalled 2.85m.
Cash flow per share-0.0034
Price/Cash flow per share--
Book value per share0.0241
Tangible book value per share-0.0006
More ▼

Balance sheet in AUDView more

TrivarX Ltd uses little debt in its capital structure as supported by a debt to capital ratio of 0.16%.
Current ratio0.7726
Quick ratio--
Total debt/total equity0.0016
Total debt/total capital0.0016
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.